BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA.
JACC Heart Fail. 2022 Jun;10(6):415-427. doi: 10.1016/j.jchf.2022.01.020. Epub 2022 Apr 6.
Up to 20% of patients in heart failure with reduced ejection fraction (HFrEF) trials are not taking diuretic agents at baseline, but little is known about them.
The aim of this study was to examine outcomes in patients with HFrEF not taking diuretic medications and after diuretic medications are started.
Patient characteristics and outcomes were compared between patients taking or not taking diuretic drugs at baseline in the ATMOSPHERE (Aliskiren Trial of Minimizing Outcomes for Patients With Heart Failure) and PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) trials combined. Patients starting diuretic medications were also compared with those remaining off diuretic drugs during follow-up. Symptoms (Kansas City Cardiomyopathy Questionnaire Clinical Summary Score [KCCQ-CSS]), hospitalization for worsening heart failure (HF), mortality, and kidney function (estimated glomerular filtration rate slope) were examined.
At baseline, the 3,079 of 15,415 patients (20%) not taking diuretic medications had a less severe HF profile, less neurohumoral activation, and better kidney function. They were less likely to experience the primary outcome (hospitalization for HF or cardiovascular death) than patients taking diuretic agents (adjusted HR: 0.77; 95% CI: 0.74-0.80; P < 0.001) and death of any cause. Commencement of a diuretic drug was associated with higher subsequent risk for death (adjusted HR: 2.05; 95% CI: 1.99-2.11; P < 0.001) and greater decreases in KCCQ-CSS and estimated glomerular filtration rate. The 5 strongest predictors of initiation of diuretic medications were higher N-terminal pro-B-type natriuretic peptide, higher body mass index, older age, history of diabetes, and worse KCCQ-CSS. In PARADIGM-HF, fewer patients who were treated with sacubitril/valsartan commenced diuretic agents (OR: 0.72; 95% CI: 0.58-0.88; P = 0.002).
Patients with HFrEF not taking diuretic medications and those who remained off them had better outcomes than patients treated with diuretic agents or who commenced them.
在射血分数降低的心力衰竭(HFrEF)试验中,多达 20%的患者在基线时未使用利尿剂,但对这些患者的了解甚少。
本研究旨在比较基线时未使用利尿剂和开始使用利尿剂的 HFrEF 患者的结局。
将 ATMOSPHERE(用阿利西尤单抗降低心力衰竭患者终点事件的试验)和 PARADIGM-HF(沙库巴曲缬沙坦与血管紧张素转换酶抑制剂用于心力衰竭患者的比较:全球终点试验)两项试验中接受或未接受利尿剂治疗的患者的特征和结局进行比较。还比较了开始使用利尿剂的患者与随访期间仍未使用利尿剂的患者。检查了症状(堪萨斯城心肌病问卷临床综合评分[KCCQ-CSS])、因心力衰竭恶化而住院、死亡率和肾功能(估算肾小球滤过率斜率)。
在基线时,15415 例患者中有 3079 例(20%)未使用利尿剂,他们的心力衰竭严重程度较轻,神经激素激活程度较低,肾功能较好。与使用利尿剂的患者相比,他们发生主要结局(因心力衰竭或心血管原因死亡而住院)和任何原因导致的死亡的风险较低(校正 HR:0.77;95%CI:0.74-0.80;P<0.001)。开始使用利尿剂与更高的死亡风险相关(校正 HR:2.05;95%CI:1.99-2.11;P<0.001),且 KCCQ-CSS 和估算肾小球滤过率的降幅更大。开始使用利尿剂的 5 个最强预测因素是 N 末端脑钠肽前体较高、体重指数较高、年龄较大、有糖尿病史和 KCCQ-CSS 较差。在 PARADIGM-HF 中,接受沙库巴曲缬沙坦治疗的患者中开始使用利尿剂的患者较少(OR:0.72;95%CI:0.58-0.88;P=0.002)。
与使用利尿剂或开始使用利尿剂的患者相比,未使用利尿剂的 HFrEF 患者和未使用利尿剂的患者结局更好。